Efficacy, safety, and tolerability of lysergic acid diethylamide for the treatment of depressive symptoms: A meta-analysis and systematic review
Journal of Psychopharmacology October 30, 2026 Andreea Chiorean, Helena Kyunghee Kim, Andrew Lustig et al.
Background: Since the Food and Drug Administration designated lysergic acid diethylamide (LSD) as a “breakthrough” treatment for generalized anxiety disorder, accumulating randomized clinical trials (RCTs) evaluating LSD’s anxiolytic effects have also reported improved depression symptoms. Evaluating the safety and efficacy of LSD in treating depression symptoms is warranted. Methods:...